Short answer
OMEROS CORP (OMER) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Omeros reported financial results for the three and six months ended June 30, 2026.
OMEROS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Omeros reported financial results for the three and six months ended June 30, 2026
- Detailed results and management commentary provided in Exhibit 99.1 press release
- Information furnished under Item 2.02, not treated as filed under specified securities-law liability provisions
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 YARTEMLEA gross revenue $32.2M, up 190% sequentially, with net revenue $28.5M
- Adjusted net income $1.8M, or $0.02 per share, versus adjusted loss $17.1M in Q1, signaling initial commercial breakeven
- Cash and short-term investments $132.0M, while operating cash flow turned positive at $4.1M for the quarter
- 2029 Notes repurchase cost $60.2M, reducing principal to $40.3M, potential conversion shares to 6.5M, and future interest by $8.6M
- EMA’s CHMP negative opinion on narsoplimab creates European approval risk despite a requested re-examination; U.S. commercialization remains the primary growth driver
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OMEROS CORP 8-K filings
Get the next OMER 8-K as it lands
Follow OMER for push alerts, or ask the research agent what this filing means.